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Summary 
The extraordinary specificity of bile duct destruction i  primary biliary cirrhosis (PBC) and the 
presence of T cell infiltrates in the portal tracts have suggested that biliary epithelial cells are the 
targets of an autoimmune r sponse. The immunodominant antimitochondrial humoral response in 
patients with PBC is directed against the E2 component ofpyruvate dehydrogenase (PDC-E2). Hitherto, 
there have only been limited reports on the characterization a d V3 usage of PDC-E2-specific loned 
T cell lines. In this study, we examined peripheral blood mononuclear cells (PBMC) for their reac- 
tivity to the entire PDC complex as well as to the El- and E2-specific omponents. We also examined 
the phenotype, lymphokine profile, and V3 usage of PDC-specific T cell clones isolated from cellular 
infiltrates from the livers of PBC patients. We report hat PBMC from 16/19 patients with PBC, 
but not 12 control patients, respond to the PDC-E2 subunit. Interestingly, this response was directed 
to the inner and/or the outer lipoyl domains, despite the serologic observation that the autoantibody 
response is directed predominantly to the inner lipoyl domain. Additionally, lymphokine analysis 
of interleukin (IL) 2/IL-4/interferon 3' production from individual liver-derived autoantigen-specific 
T cell clones suggests that both T helper cell Thl- and Th2-1ike clones are present in the liver. 
Moreover, there was considerable heterogeneity n the T cell receptor for antigen (TCIk) V3 usage 
of these antigen-specific autoreactive T cell clones. This is in contrast to murine studies in which 
animals are induced to develop autoimmunity b specific immunization and have an extremely imited 
T cell V~ repertoire. Thus, our data suggest that in human organ-specific autoimmune diseases, 
such as PBC, the TClk V3 repertoire is heterogenous. 
p trimary biliary cirrhosis (PBC) 1 is an idiopathic hepatic 
disorder characterized bythe presence of autoantibodies 
to mitochondrial ntigens (AMA), lymphoid infiltrates in 
the portal tracts of the liver, bile duct destruction, and prolifer- 
ation of bile duct epithelial cells (1-3). The immunodominant 
response of AMA is directed at the E2 component of pyru- 
1 Abbreviations used in this pa/x,r: AMA, autoantibodies to mitochondrial an- 
tigens; PBC, primary biliary cirrhosis; PDC-E1, -E2, E1 and E2 components 
of pyruvate d hydrogenase, respectively; PSC, primary sclerosing cholangitls. 
vate dehydrogenase (PDC-E2) (4, 5). The reactive region of 
PDC-E2 recognized by autoantibodies has been mapped and 
includes pecific recognition of the inner lipoyl domain and, 
to a 100-fold lesser extent by sera titration, the outer lipoyl 
domain (6, 7). 
The extraordinary specificity of bile duct destruction i  
PBC, the presence of lymphoid infiltrates in the portal tracts, 
and the aberrant expression of class II antigens on biliary epi- 
thelium, suggest hat biliary epithelial cells are the targets 
of an intense autoimmune r sponse (8-10). Although it has 
been suggested that the infiltrating T cells are oligoclonal, 
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there haw been only limited report~ on characterization of
PDC-E2 specific-cloned T cell lines (11-15). In this study, 
we not only studied PBMC but also examined cells cultured 
from liver tissues from patients with PBC for reactivity to 
the entire PDC complex, and to the El- and E2-specific sub- 
components. We report the response of patients' peripheral 
blood T cells to different PDC components and, in addition, 
the phenotype, lymphokine profile, and V~ usage of PDC- 
specific cloned T cell lines isolated from cellular infiltrates 
from the livers of PBC patients. Based on cytokine profiles, 
these PDC-E2-specific loned T cell lines were noted to be 
composed of both Thl-  and Th2-1ike cells. More importantly, 
unlike in animal models of autoimmunity, there was confid- 
erable heterogeneity of TCR V~/usage in autoreactive T cell 
clones specific for PDC-E2. 
Mater ials and Methods  
Clinical S~cirnens. Blood was collected from 19 female subjects, 
ages 42-65 yr, with PBC (16); all were known to be positive for 
AMA by use of Hep-2 cells and immunofluorescence. All 19 sub- 
jects were, by histology, considered to have stage II through stage 
IV disease. In addition, 12 control subjects were studied. These 
included eight healthy volunteers ( ix female, two male) and four 
patients with primary sclerosing cholangitis (PSC) (three female, 
one male). The sera from all subjects were analyzed by immuno- 
blotting with beef heart mitochondria and by ELISA with recom- 
binant proteins (7). From this analysis, sera from 19/19 patients 
with PBC reacted with PDC-E2, 9/19 reacted with PDC-Elc~, 
and 13/19 reacted with branched-chain ketoacid ehydrogenase. 
None of the control subjects howed any detectable r activity. Fi- 
nally, liver tissue was obtained at transplantation from two patients 
with PBC (one female and one male) and one male patient with 
PSC, ages 52-65 yr. 
Antigen Preparation. The native antigens used for in vitro stim- 
ulation were prepared from beef heart mitochondria (17, 18); sera 
from PBC patients react equally well with both human and bovine 
mitochondrial ntigens (4). First, a parbomb was used to disrupt 
mitochondria, followed by polyethylene glycol fractionation. After 
homogenization, the PDC fraction was centrifuged through 7.5, 
10, and 15% sucrose gradients at 28,000 rpm in a SW27 rotor 
at 4~ for 4 h. The resulting pellet was then fractionated into the 
El, E2, and E3 components by use of a Sephacryl s400 column 
(18). Fractions were collected, analyzed for purity by SDS-PAGE, 
and filtered through a 0.22-g fiher. In addition, the two lipo/c 
acid-binding regions of human PDC-E2 were prepared from our 
previously defined recombinant human PDC-E2 (pHumPDC-E2- 
2A) (6, 7). As a control, another mitochondrial ntigen, bovine 
malic dehydrogenase (Sigma Chemical Co., St. Louis, MO) was 
studied. 
Briefly, all domains were derived by PCR using purified 
pHumPDC-E2-2A as a template with EcoRl cloning sites at both 
ends. The resulting constructs were cloned into the pGEX-2T 
system and treated with thrm-nbin to cleave the rPDC from the 
glmathione-s-transferase moiety. Positive clones were selected by 
ELISA and immunoblotting and subsequently sequenced. The con- 
structs used in this study were amino acid residues 1-98 (E2L1; 
containing the otrter lipoyl domain), 120-233 (E2L2; containing 
the inner lipuyl domain), and 1-233 (E2L1 + L2). All fragments 
were then purified after thrombin treatment. 
Culture and Proliferation of PBMC. PBMC were purified by den- 
sity centrifugation, washed, and incubated in media (X-Vivo 15; 
Bio Whittaker, WalkersviUe, MD) containing 4% T-Stim (Col- 
laborative Research, Inc., Bedford, MA) overnight at 37~ in 10% 
COs. Cellular proliferation of the PBMC was measured with the 
[3H]thymidine assay (19). Briefy, 2 x 105 PMBC were washed 
and incubated with the following antigens: PDC at 10, 0.1, and 
0.001 #g/ml; PDC-E2 at 50, 10, and 0.001 #g/ml; PDC-E1 at 
10, 0.1, and 0.001/xg/ml; and, for purposes of control, BSA at 
10 gg/ml. The antigens were diluted in X-Vivo 15 media containing 
1% T-Stim and incubated with the isolated PBMC for 6 d at 37~ 
in 10% CO2. On day 6, 1/xCi of [3H]thymidine was added to 
each well, incubated for 18 h, harvested, and counted in a scintilla- 
tion counter (Betaplate; Wallac, Inc., Gaithersburg, MD). 
Liver-derived T Cell Clones. The liver was minced into 1-cm 3 
pieces and digested with 1 mg/ml type I collagenase (Sigma Chem- 
ical Co.) in HBSS for 2 h at 37~ with agitation. The digested 
material was then washed three times in HBSS and the pellet purified 
by density centrifugation as above. The cells at the density gra- 
dient interface were collected and washed three times in PBS and 
cultured in 24-well plates in 4% T-Stim in X-Vivo 15 media t 37~ 
for 5-7 d. The cells were then cloned by limiting dilution to 0.3 
cells/well. After '~2 wk, the clones were expanded into 24-well 
plates by use of irradiated JY feeder cells (20) at 5 x l0 s cells/ml 
and 4% T-Stim. Positive T cell clones were identified by the prolifer- 
ation assay described above except hat two sources of APC were 
used for this study. One consisted of EBV-transformed cell lines 
derived from the PBMC of the PBC patients (21). The second source 
was an enriched population of adherent cells that were isolated from 
the PBMC from normal adult volunteers who shared the MHC 
class II type with the PBC patients being studied. The difference 
between EBV-transformed B cells versus MHC class II matched 
"professional" APC was quite marked. For example, clone 1, de- 
rived from patient 1 when cocultured with antigen-pulsed autolo- 
gous irradiated EBV-transformed cells, gave a proliferative response 
of 7,526 _+ 119 cpm (mean _+ SEM) with an IL-2 production of 
4.6 U/ml. In contrast, he same T cell clone, when cocultured with 
the antigen-pulsed nriched population of MHC class II identical 
adherent APC resulted in an increased proliferative response of 
29,744 _+ 166 cpm and an IL-2 concentration of 53.9 U/ml. The 
difference in the relative responses to the same antigen presented 
by autologous irradiated EBV-transformed cells compared with 
MHC class II identical adherent cells was not secondary to dose 
of antigen and/or differences in kinetics of the response (data not 
shown). Each cloned T cell line was assayed for antigen-specific 
proliferative responses by use of both autologous irradiated EBV- 
transformed cells lines as well as adherent cells as APC. However, 
the data presented here are from the studies performed with the 
adherent cell APC preparations. 
Tissue typing of MHC class I and II alleles expressed by the 
EBV-transformed cell lines was defined by use of standard serolog- 
ical tissue typing techniques. MHC class II typing was further 
refined and confirmed by use of molecular typing techniques. These 
data allowed us to select for individuals who shared the identical 
MHC class II type for use as a source of APC in our assays. 
Adherent APC were pulsed overnight with media alone (con- 
trol) or antigen at optimum concentrations of 10 #g/ml PDC-E1, 
25 #g/ml PDC-E2, 0.1 gg/ml E2L1, and 0.1/xg/ml E2L2. Malic 
dehydrogenase was also t~sed at concentrations of 0.1, 1.0, and 10 
gg/mI for purposes of antigen specificity. The antigen-pulsed APC 
were dispensed into 96-well microtiter plates in a volume of 0.1 
ml containing 2 x 105 cells in media consisting of KPMI 1640 
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supplemented with 100 U/ml penicillin, 100 #g/ml streptomycin, 
2 mM t-glutamine, 2 x 10 -s M 2-mercaptoethanol, and 15% 
heat-inactivated pretested human AB plasma. The frequency of the 
adherent cell subsets was confirmed by FACS | analysis (Becton Dick- 
inson & Co., Mountain View, CA) to be 5-9% CD3 + , 55-75% 
CD14 +, and 24-36% CD20 + cells. To triplicate wells was added 
either 0.1 ml of media lone (control) or 0.1 ml of media containing 
10 s of the cloned T cell line being analyzed for proliferation. The 
cultures were incubated at 37~ in a 7% CO2-humidified at- 
mosphere. At 48 h, 0.1 ml of the supernatant from each well was 
aspirated and assayed for levels of lb2 by use of the Ib2-dependent 
HT-2 cell line as described elsewhere (15). Recombinant human 
IL-2 (courtesy of Roche Laboratories, Nutley, NJ) was used to de- 
rive a standard curve. The cultures were then fed fresh media and 
allowed to incubate for an additional 3 d, then pulsed with 1 #Ci 
of methyl-[3H]thymidine (2 Ci/mmol; New England Nuclear, 
Boston, MA) in 0.02 ml of media. Cultures were harvested 16-18 h 
later and the mean uptake of [3H]TdR was determined. Superna- 
tants from clones derived from patient 1 were also assayed for Ib4 
and IFN-q/by use of EIA kits (Genzyme Corp., Boston, MA) and 
a bioassay. 
Cryopreserved aliquots of each cloned T cell line were thawed 
and cultured in media containing 10 U/ml of recombinant human 
IL-2 for 3-7 d. The expanded cell population was then allowed to 
rest for 24-48 h in media without Ib2 and layered over a Ficoll- 
Hypaque gradient. The cells at the interface were washed with media 
and then assayed for antigen-specific proliferation. Cloned T cell 
lines showing specificity for El, E2, E2L1, E2L2, or mixed specifidty 
were subsequently maintained by coculture with the appropriate 
antigen pulsed normal matched APC at a ratio of 1:2. For repro- 
ducibility studies, such maintained cells were washed and layered 
onto Ficoll-Hypaque gradients. The cells at the interface were col- 
lected, washed twice in media, and then assayed for antigen-specific 
proliferation and IL-2 production. In cases in which a lack of con- 
cordance was noted between data obtained with the IL-2 readout 
and [3H]TdR uptake, the clones were studied in further detail by 
use of APC pulsed with a broad range of antigen concentrations 
(from 0.001 to 25 gg/ml for PDC-E2 and from 0.001 to 10 gg/ml 
for PDC-E1, E2L1, and E2L2) in efforts to rule out differences, 
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if any, that could be secondary to antigen dose. In addition, each 
clone was also tested for MHC-restricted responses by coculture 
of the cloned T cell line with non-MHC compatible APC pulsed 
with the same antigen at the same dose used with the MHC- 
compatible APC. 
A total of 254 T cell clones were obtained from liver tissues from 
PBC patient 1, 196 clones from PBC patient 2, and 156 clones 
from the control patient with PSC. 
Phenotypic Analysis. Antigen-specific T cell clones from both 
patients were phenotyped for CD4, CD8, TCR-cffB and CD45RO 
by standard flow microfluorometric techniques by use of FACS- 
Star Plus | (Becton Dickinson & Co., Mountain View, CA) and 
fluorescent conjugated mAbs. The V/~/usage of the antigen-specific 
T cell clones obtained from the liver tissues of patients 1 and 2 
was analyzed by PCK. 107 cells of each clone were collected, snap- 
frozen, and stored at - 70=0. TCR V/3 expression was determined 
by PCR (22). Each PCR reaction contained specific oligonucleo- 
tide primers to expand aparticular V~/gene segment (170-220 bp) 
as well as an cr chain constant gene segment (600 bp) (23). The 
primer used to identify V~8 expression does not distinguish be- 
tween VB8.1 and V/~/8.2, and the primer used to identify VB6 ex- 
pression does not distinguish between VB6.1 and V~6.3. Amplified 
products were separated on 2% agarose gels and identi~ed by use 
of ethidium bromide. 
Results 
PBMC Response Of 19 PBC patients tudied, PBMC from 
16 gave a proliferative response ranging from two- to sixfold 
above background to one or more mitochondrial antigens 
(Table 1, Fig. 1). A positive response was designated as at 
least two SD above the mean of the media control for each 
patient. Of  these 16 patients, PBMC from 10 produced a 
two- to sixfold response to the PDC-E2 subunit, which was 
optimal at 50 gg/ml  (Fig. 1). PBMC from 3 of these 16 pa- 
tients also responded to PDC-E1 (Fig. 2 A), and 4 demon- 
strated reactivity to both the PDC-E1 and PDC-E2 compo- 
9 MEDIA 
[ ]  PDC-E2 50.ug/ml 
[ ]  PDC-E2 10,~g/ml 
[ ]  PDC-E2 0.1 ,ug/ml 
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4 5 6 7 8 9 
PATIENT # 
1 0 Cont ro l  
Figure 1. In vitro proliferative 
response (PBMC) from 10 patiems 
with PBC and a representative con- 
trol subject cultured with media, 
various concentrations of PDC-E2, 
and BSA. A positive response was 
at least two standard eviations 
above the mean of the media con- 
trol. The data re expressed as mean 
cpm _+ SEM. 
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Figure 2. PBMC from patients with PBC were stimulated with either PDC-E1 (A), the PDC-E2 outer lipoyl domain (E2L1) (B), the inner lipoyl 
domain (E2L2) (C), or a combination ofthe two domains (E2LI+L2) (D). (A) Three representative patients and a negative control are shown. Max- 
imum stimulation was seen most often with a PDC-E1 antigen concentration f 10 #g/ml. (B) Four representative patients who responded to a 0.1- 
#g/ml concentration f E2L1 are shown. Note the substantial response directed against the outer lipoyI domain of PDC-E2. (C) Three representative 
patients that responded to the inner lipoyl domain (E2L2) are illustrated. Note the particularly strong response of patient 2. (D) Four representative 
patients who responded to the E2LI+L2 domains at a concentration f 10/~g/m] are shown. Patient 4 produced aparticularly strong response when 
both domains were tested. The numbers assigned to each of the patients depicted were for graphing purposes only and do not reflect he same patient 
in each graph9 A positive response was designated astwo SD above the mean of the media control and are expressed asmean cpm _+ SEM. Representative 
negative control subjects were included in experiments and are shown in all graphs. 
Table 1. Proliferative Response of PBMC from Patients with PBC to PDC Antigens 
Antigen 
E2L1 E2L2 E2L1 + L2 
Group Positive/total* PDC PDC-E1 PDC-E2 (aal-98) (aa120-233) (aal-233) 
PBC 16/19 1/19 7/19 s 10/19 6/11 II 4/11 4/11 
(84%) (5~ (4707o) (5207o) (54%) (36~ (36%) 
Control* 0/12 0/12 0/12 0/12 0/12 0/12 0/12 
(0%) (0%) (007o) (007o) (007o) (0%) (007o) 
* Positive to one or more mitochondrial ntigens. 
* Controls include eight healthy and four PSC samples. 
s Three of the seven reactive patients reacted only to PDC-E1. 
If 2 of 11 patients responded to both the outer and inner lipoyl domains. 
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nent (Table 1). Interestingly, PBMC from only 1 of 19 patients 
responded to the entire PDC complex (Table 1). 
PBMC from 11 PBC patients and 12 control subjects were 
also tested for reactivity to the outer (E2L1) and inner (E2L2) 
lipoyl domains. Of these, 6/11 or 54% reacted to the outer 
domain region (Fig. 2 B) compared with 4/11 (36%) to the 
inner lipoyl domain (E2L2) (Fig. 2 C). PBMCs from 2 of 
11 patients responded to both the E2L1 and E2L2 regions. 
PBMCs from 1 of 11 patients did not show a detectable r - 
sponse to any of the antigens tested. Surprisingly, when the 
construct containing both domains (E2L1 + L2, amino acids 
1-233) was studied, only 4 of these same 11 patients howed 
a proliferative r sponse (Fig. 2 D). Moreover, at comparable 
concentrations, one of these latter four patients responded 
only to E2L1 + L2 and full-length PDC-E2 antigens, and 
not to the individual E2L1 and E2L2 domains. Only 3 of 
11 patients responded tothe full-length PDC-E2 antigen and 
one or both of the E2L1 or E2L2 domains. The eight healthy 
and four PSC control subjects tested showed no significant 
response to any of the antigens used here. 
Liver-derived Cloned T Cells. Of the 254 clones generated 
from PBC patient 1, 28 showed specificity for one or more 
of the mitochondrial ntigens (Table 2). Of these 28 clones, 
6/28 demonstrated specificity for PDC-E2, 7/28 showed 
specificity for PDC-E1, 8/28 for the E2L1 domain, and 11/28 
for the E2L2 domain of PDC-E2 (Table 2). Data from repre- 
sentative clones are illustrated in Fig. 3, A-/) Only four clones 
from patient 1 showed specificity for more than one antigen; 
this includes two clones that showed specificity for both 
PDC-E1 and E2L2 and two clones positive for both PDC-E2 
and E2L1. Similarly, 23 antigen-specific clones were found 
out of the 196 clones isolated from the liver of PBC patient 
2 (Table 2). Of these 23 clones, 8 (35%) showed specificity 
for PDC-E2 and only 2/23 were positive for the E2L1 re- 
gion. The majority of the clones, 19/23 or 83%, responded 
to the second lipoic acid domain, E2L2. Data from represen- 
tative clones are illustrated in Fig. 4, A-C. Unlike patient 
1, there were no PDC-El-positive T cell clones derived from 
this liver. Interestingly, only one clone, 2-123, responded to 
PDC-E2, E2L1, and E2L2. This patient had four clones that 
responded to both PDC-E2 and E2L2. This is in contrast 
to clones from patient 1, in which none of the dual-positive 
clones responded to both of those antigens imultaneously. 
Overall, these responses were quite reproducible with respect 
to both proliferation and Ib2 production when data from 
three different assays were compared (Table 3). When tested 
with similar concentrations of the same antigen-pulsed MHC- 
incompatible APC, the cpm values were at background levels 
(data not shown). In addition, none of the clones showed 
proliferative responses or IL-2 production upon coculture with 
malic dehydrogenase-pulsed MHC-matched APC. Finally, 
none of the 156 PSC control iver clones showed any detect- 
able response to the antigens tested. 
Supernatant fluids derived from antigen-stimulated cultures 
of the T cell clones from both patients were assayed for IL-2 
production. Clones from patient 1 were also tested for IL-4 
and IFN-3' production. As seen in Table 4, only 4 of the 28 
cloned T cells from patient 1 appeared to secrete IL-4. The 
rest of the cloned T cell lines from this patient secreted either 
IL-2, IFN-3', or both. Based on the concept that II--2/IFN-3, 
secretion isa property of Thl-like clones and IL-4 a property 
attributed to Th2-1ike clones, these data suggest adominant 
Thl profile for these T cell clones. Clones from patient 2 
showed strong IL-2 production, especially when stimulated 
with PDC-E2 (Table 5). 
Phenotypic analysis of the 28 liver-derived T cell clones 
from patient 1 revealed that 27/28 were CD4 § with 1 
CD4/CD8 dual-positive clone (Table 4). Out of 23 clones 
from patient 2, 21 were CD4 § and 2 were CD4/CD8 § 
(Table 5). 9 of 28 clones from patient 1 were CD45RO +, 
while 3 were weakly CD45RO § For patient 2, 2 out of 
23 clones were CD45RO § These data suggest the presence 
of at least 32% antigen-specific memory T cells in patient 1. 
The TCR phenotype of all but one of the clones from 
patient 1 were or/3. Analysis of V/3 usage was performed, 
and the antigen-specific T cell clones showed a remarkably 
heterogeneous repertoire (Table 4). For example, among the 
30 E2L2-reactive clones with identifiable V/5 expression from 
both patients, at least 14 different V/~s were involved in the 
response. However, there appeared to be a slight increase with 
respect to V/3 3, 6.1, 13.1, and 13.2. V/38 and VB3 utiliza- 
tion was associated with all of the mitochondrial ntigens 
tested. 
The TCR phenotype of the clones from patient 2 were 
all a/8 (Table 5). Analysis of VB usage revealed that 3 of 8 
clones reactive with PDC-E2 expressed V/58.1/8.2, 4 of 19 
Table 2. Autoantigen-specific T Cell Clones Isolated from the Liver of Patients with PBC 
Positive/total PDC-E1 E2L1 E2L2 E2L1 + L2 
Patient clones PDC-E2 PDC-E1 only (aa 1-98) (aa 120-233) (aa 1-233) 
PBC 1 28/254 6/28 7/28 5/28 8/28 11/28 0/28 
(21"7o) (25%) (18%) (29%) (39%) (0%) 
PBC 2 23/196 8/23 0/23 0/23 2/23 19/23 1/23 
(35%) (0%) (0%) (9%) (83%) (4%) 
Control (PSC) 0/156 0/156 0/156 0/156 0/156 0/156 0/156 
(0%) (0%) (0%) (0%) (0%) (0%) 
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Figure 3. T cell clones derived from the liver of patient 1 were stimulated with various mitochondrial ntigens and [3H]thymidine uptake was mea- 
sured. Four representative positive clones and one negative clone for PDC-E1 (A), PDC-E2 (B), E2L1 (C), and E2L2 (D) are illustrated. The data 
are presented as mean cpm _+ SEM. 
clones reactive with E2L2 expressed V36.1 and 3 of 19 ex- 
pressed V33. Overall, the expression of these gene segments 
appeared to be increased compared with that expected in 
normal blood (for V~8 and V36.1, 17% of the clones vs. 
3-7% in blood; for V/33, 22% vs. 1-8% in blood). 
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Discussion 
PBC is best classified as belonging to a group of sponta- 
neous autoimmune diseases in which specific organ systems 
are targeted for destruction. Included in this group are my- 
asthenia gravis, multiple sclerosis, autoimmune thyroiditis, 
and type 1 diabetes (23-26). As in primary PBC, there has 
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T cell clones derived from the liver of patient 2 were stimu- 
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(A), E2L1 (B), and E2L2 (C) are illustrated. As noted in the text, there 
were no liver-derived T cell clones from this patient that reacted to PDC-E1. 
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been difficulty in obtaining and analyzing samples from the 
target organ. By necessity, many investigators have chosen 
to work with peripheral blood T cells to define specificity 
and T cell receptor usage, even though the relevance of these 
cells to the organ-infiltrating T cells is uncertain (27, 28). 
Our study is therefore significant in that it defines the pheno- 
type and specificity of T cells derived from damaged livers. 
In addition, the specificity of these cells matches that of a 
major antibody response that can be detected early in the 
disease process. 
PDC-E2 contains two lipoic acid-binding regions (E2L1 
and E2L2), which share a 63% sequence homology (7). In 
previous tudies by our laboratory, patient sera were tested 
for antibody activity against hese two lipoyl domains, and 
80-90% of patients how activity to both domains. How- 
ever, antibody titers to the inner domain are frequently 100- 
fold greater. Previous data suggested that the B cell epitopes 
for these two domains had partial cross-reactivity based on 
selective absorption data (29). In the current study, 54% of 
patients howed aperipheral T cell response to the outer lipoic 
acid-binding region, while only 36% responded tothe inner 
lipoyl domain. Thus, the peripheral T cell response appears 
to be directed against wo entirely separate regions of the 
PDC-E2 molecule. Surprisingly, only 4 of the 10 patients 
that responded to the E2L1 and E2L2 domains also reacted 
to the full length PDC-E2 molecule. This may indicate that 
an epitope that overlaps the E2L1 and E2L2 proteins is present 
within the full length PDC-E2 molecule but is not present 
in either of the smaller lipoyl domains. It is less likely that 
the data are secondary to antigenic differences between spe- 
cies (30), but it is possible that the processed forms of the 
entire PDC-E2 molecule may yield several different peptide 
fragments, ome of which may have a higher affinity for the 
class II molecule and thereby not allow efficient presentation 
of the autoantigenic peptide. Indeed, biliary epithelial cells 
may also have a different composition of proteases than mono- 
cytes or EBV cells. Finally, this phenomenon could also be 
explained by a failure to efficiently process the large PDC 
complex. 
The peripheral T cell PDC-E1 response was also examined 
in this study. Autoantibody reactivity to PDC-E1, in both 
this and previous tudies (31), is found in about half of pa- 
tients with PBC. In contrast, nearly all patients have activity 
for PDC-E2. Interestingly, if one compares the T cell response 
in the PBMC and T cell clones of patient 1 to PDC-E1 and 
PDC-E2 (52%), they are nearly equal. This is in marked con- 
trast o the antibody profile. It is recognized that T cells recog- 
nize epitopes distinct from B cells, as highlighted by hapten- 
carrier systems. Thus, epitopes of PDC-E1 may induce T cell 
activation, which may secrete cytokines that induce B cell- 
specific responses to other moieties of the PDC. Another pos- 
sibility is that the PDC-E2-specific T cells home preferen- 
tially to the liver and are less abundant in the periphery. 
The difference in T cell specificity between patients 1and 
2 was also remarkable. For example, 25% of the cloned T 
cell lines from patient I showed specificity for PDC-E1, while 
none of the T cell clones from patient 2 showed similar 
specificity. In addition, 83% of the cloned T cell lines from 
Table 3. Reproducibility of Antigen-specific Proliferation and Lymphokine Responses by Representative T Cell Clones from 
PBC Patients I and 2 
Antigen IL -2(1)  
Clone specificity cpm (1)* U/ml cpm (2) IL-2 (2) cpm (3) IL-2 (3) 
1-11 E2L2 7,647 +_ 76 21.0 5,988 _+ 24 7.7 8,667 _+ 104 8.7 
1-72 PDC-E1 9,422 + 137 15.6 7,642 _+ 101 9.6 9,824 _+ 134 8.9 
1-90 PDC-E2 9,647 _+ 142 39.9 8,456 _+ 68 18.6 8,125 + 71 26.3 
1-105 E2L2 6,006 _+ 108 5.9 9,924 + 100 4.8 9,376 _+ 76 5.7 
1-122 E2L1 8,145 _+ 145 28.7 4,738 _+ 85 6.9 5,145 + 48 6.9 
2-34 E2L2 8,014 + 137 18.2 4,393 _+ 22 12.6 9,014 _+ 147 14.6 
2-35 E2L1 5,055 _+ 70 22.9 9,122 _+ 139 14.5 6,926 _+ 48 9.2 
2-177 PDC-E2 18,374 _+ 100 11.2 22,667 + 30 15.4 8,456 _+ 100 5.9 
* Values are expressed as mean _+ SEM. 
Table 4. Response and Phenotype ofAntigen-specific T Cell Clones from PBC Patient 1 
Clone Antigen specificity S.I. Lymphokine CD TCR V3 CD45RO 
1 PDC-E2 38 IL-2*, IFN CD4 c~3 1 
3 E2L1 19 IL-2, IFN CD4 c~3 5.1 
9 E2L2 29 IL-2 CD4 a3  13.1 
11 E2L2 16 IL-2 CD4 ? NEG* 
16 PDC-E1 80 IL-2, IFN CD4 ol3 8.1, 20 S 
19 PDC-E2, E2L1 60, 3411 IL-2 CD4 c~3 2 
20 PDC-E1, E2L2 15, 57 IL-2 CD4 c~3 2 
21 E2L1 12 IL-2, IFN CD4 c~3 7 
23 E2L1 27 IL-2, IL-4 CD4 ? 3 
27 E2L2 17 IL-2, IFN CD4 ? 1 
43 PDC-E2 19 IL-2, IFN CD4 c~3 4 
47 E2L2 18 IL-2, IFN CD4 c~3 13.1 
72 PDC-E1 29 IL-2 CD4 c~3 NEG* 
75 PDC-E2 2 IL-2, IFN CD4 a3  2 
82 E2L1 59 IL-2 CD4/CD8 cr NEG* 
83 E2L1 95 IL-2 CD4 cr 5.1 
84 E2L2 23 IL-2, IFN CD4 c~3 5.1, 13.2 
90 PDC-E2 14 IL-2, IFN CD4 aB 14 
94 PDC-E1 77 IL-2, IL-4 CD4 o~3 3 
105 E2L2 21 IL-2, IFN CD4 a3  6.1, 13.2 
121 E2L2 23 IL-2 CD4 cr 3, 10 
122 PDC-E2, E2L1 11 IL-2 CD4 cr 13.1, 13.2 
123 E2L2 27 IL-2 CD4 a3  7 
152 PDC-E1 15 IL-2 CD4 c~3 2 
161 PDC-E1 22 IL-2 CD4 c~3 NEG* 
170 E2L2 17 IL-4 CD4 c~fl 8.1 
219 E2L1 28 IL-4 CD4 c~3 8.1 
230 PDC-E1, E2L2 16, 38 IL-2 CD4 cx3 ND 
Positive 
Weak 
Negative 
Negative 
Positive 
Weak 
Weak 
Positive 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Positive 
Positive 
Positive 
Negauve 
Positive 
Negattve 
Positive 
Positive 
Negat,ve 
Negattve 
Negative 
Negative 
Negative 
Negative 
* The range of IL-2 U/ml values was 1.9-53.9. 
* The V3 expressed was not identified with the panel of V3 primers used in this analysis. 
S Although designated V~8.1, the primer used does not distinguish between 8.1 and 8.2. Similarly, the primer used to identify V36 members will 
amplify V/36.1, 6.2, and 6.3 gene segments. 
II Where more than one value is given, they correspond to the order of the antigens. 
S.I., stimulation index. 
Table 5. Response and Phenotype of Antigen-specific L ver T Cell Clones.from PBC Patient 2 
Antigen 
Clone specificity -S . I .  Lymphokine CD TCR V~ CD45RO 
3 PDC-E2 78 IL-2* CD4 ct/3 8.1 
12 E2L2 2 IL-2 CD4 o~B 14 
25 E2L2 6 IL-2 CD4 ol/3 15 
34 E2L2 12 IL-2 CD4 t~/3 13.1,13.2 
35 E2L1 9 IL-2 CD4 ctB 3 
38 PDC-E2 73 IL-2 CD4 ct~ 8.1 
41 E2L2 27 IL-2 CD4 c~ 3 
43 E2L2 10 IL-2 CD4 t~/3 3 
51 E2L2 16 IL-2 CD4 c~B 13.1 
59 E2L2 57 IL-2 CD4 o~/3 12 
63 E2L2 13 IL-2 CD4 ct/3 2 
78 PDC-E2 27 IL-2 CD4 o~B 3,8.1,11 
85 PDC-E2, E2L2 57, 9s IL-2 CD4 or/3 15 
91 E2L2 20 IL-2 CD4/CD8 ct/3 6.1 
108 E2L2 14 IL-2 CD4/CD8 ctB ND 
118 PDC-E2, E2L2 26, 9 IL-2 CD4 o~ 6.1 
123 PDC-E2, E2L1, E2L2 43, 20, 22 IL-2 ? oL~ 20 
125 E2L2 23 IL-2 CD4 tx/3 13.2 
139 E2L2 1.4 IL-2 ? olB 8.1 
146 E2L2 19 IL-2 CD4 o~/3 5.1 
156 E2L2 3 IL-2 CD4 c~B 6.1 
177 PDC-E2, E2L2 28 IL-2 CD4 or/3 6.1 
179 PDC-E2, E2L2 24, 9 IL-2 CD4 o~/3 3 
Negative 
Negative 
Negative 
Negative 
Negative 
Negauve 
Negauve 
Negauve 
Negauve 
Negative 
Negauve 
Negauve 
Negauve 
Negauve 
Negative 
Negative 
Negauve 
Positive 
Negative 
Positive 
Negative 
Negative 
Negative 
* The range of IL-2 U/ml was 5.4-53.4. 
* Although designated VBS. 1, the primer used oes not distinguish between 8.1 and 8.2. Similarly, the primer used to identify VB6 members will 
amplify V/36.1, 6.2 and 6.3 gene segments. 
5 Where more than one value is given, they correspond tothe order of the antigens. 
patient 2 responded to E2L2, in contrast o only 39% for 
patient 1. These differences could be attributed to chance 
during cloning or could be due to a difference in the stage 
of the liver at the time of transplant. A final possibility could 
be MHC differences and their ability to recognize and present 
the various antigens. These data gain raise the issue of whether 
there is preferential homing of the E2L2-reactive T cells to 
the liver and whether the epitope recognized by these E2L2- 
specific T cells may cross-react with a non-PDC antigen, as 
has been suggested by previous histologic studies (32). Also 
of great interest were the number of clones that responded 
to more than one antigen. The combination ofantigens was 
also somewhat unexpected. For example, patient 1 had two 
clones, one of which had a single VB, that responded toboth 
PDC-E1 and E2L2. Perhaps there is an epitope that is common 
to both antigens, or, less likely given the single V/3 usage, 
they were not homogenous clones. Patient 1 also had two 
dual PDC-E2-E2Ll-reactive clones. Again, there was single 
V/3 usage in both of these pairs. Although it is not as sur- 
prising to find shared reactivity to these two antigens, it is 
731 Van de Water et al. 
interesting that there is seldom reactivity to all three antigens 
derived from PDC-E2 by a single clone (1 out of 51 clones 
tested). These studies uggest that there is in fact more than 
one T cell epitope on the PDC-E2 antigen and that some 
of these may have shared epitopes, while others are unique 
to the two lipoyl regions. Moreover, there is a gap of 22 amino 
acids between E2L1 and E2L2 that is unique to the entire 
PDC-E2 complex which may also contain an additional epi- 
tope. Further studies with synthetic peptides may clarify this 
issue. 
The T cell receptor V~ repertoire utilized by PDC-reactive 
clones infiltrating the liver was remarkable in its heteroge- 
neity. This heterogeneity was especially apparent within 
subsets that responded to particular domains. For example, 
in both patients, E2L2-reactive T cell clones utilized mul- 
tiple different V/3s, and only a few examples of repetitive VB 
usage were noted. This contrasts greatly with studies of pe- 
ripheral blood-cloned T cell lines in multiple sclerosis (23), 
but is consistent with other studies (27, 33). It also is dis- 
tinct from autoimmune T cell receptor epertoires defined 
in mice immunized with autoantigens (34). A few V3s were 
also noted to be possibly overutilized, but the relatively small 
number of clones used to estimate total repertoire limits any 
definite conclusions. Since the patients tudied were advanced 
in their disease process, additional epitopes may have elicited 
responses related to the tissue damage analogous to deter- 
minant spreading. Further observations involving patients at 
different stages of disease will help to clarify these interesting 
issues. 
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